Amgen Inc. (AMGN) Stake Maintained by Weaver C. Barksdale & Associates Inc.
Weaver C. Barksdale & Associates Inc. continued to hold its stake in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,576 shares of the medical research company’s stock at the end of the 2nd quarter. Amgen accounts for approximately 1.7% of Weaver C. Barksdale & Associates Inc.’s holdings, making the stock its 13th biggest position. Weaver C. Barksdale & Associates Inc.’s holdings in Amgen were worth $1,477,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of AMGN. TrimTabs Asset Management LLC grew its holdings in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC raised its position in Amgen by 19.0% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its position in Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. American Beacon Advisors Inc. bought a new stake in Amgen in the 1st quarter valued at approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC bought a new stake in Amgen in the 1st quarter valued at approximately $121,000. Institutional investors own 78.10% of the company’s stock.
A number of research firms have weighed in on AMGN. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $189.00 price target on shares of Amgen in a research report on Friday, June 30th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Credit Suisse Group set a $177.00 price objective on shares of Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Morgan Stanley lifted their price objective on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, June 13th. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $174.00 price objective (up previously from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $188.41.
COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/amgen-inc-amgn-stake-maintained-by-weaver-c-barksdale-associates-inc/1605805.html.
Amgen Inc. (NASDAQ AMGN) traded down 0.1908% during mid-day trading on Tuesday, reaching $186.8129. The company had a trading volume of 814,523 shares. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10. The company has a market capitalization of $136.31 billion, a price-to-earnings ratio of 17.0155 and a beta of 1.36. The stock has a 50-day moving average of $179.40 and a 200 day moving average of $169.72.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the prior year, the firm posted $2.84 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post $12.57 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.46%. The ex-dividend date was Tuesday, August 15th. Amgen’s dividend payout ratio is presently 41.93%.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.